---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-071512"
form_type: "8-K"
ticker: "CARL"
cik: "0001794546"
company_name: "CARLSMED, INC."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:24:53.603373+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Carlsmed Q4 revenue $15.2M (+61% YoY); FY rev $50.5M (+86%); guides FY2026 $70-75M

## Summary
- Q4 rev $15.2M (+61% YoY), FY rev $50.5M (+86% YoY). Gross margin 76.5% Q4, 75.3% FY.
- Net loss Q4 ($8.6M), FY ($29.6M); adj. EBITDA loss Q4 ($8.4M), FY ($28.4M).
- Cash, cash equivalents, restricted cash, and ST investments $109.9M at Dec 31, 2025.
- FY2026 revenue guidance $70-75M, representing ~44% growth at midpoint over 2025.
- 2-year data showed 74% reduction in revision rates for aprevo® lumbar vs non-aprevo.

## SEC filing metadata
- accession: 0001193125-26-071512
- form_type: 8-K
- ticker: CARL
- cik: 0001794546
- company_name: CARLSMED, INC.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1794546/000119312526071512/0001193125-26-071512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1794546/000119312526071512/carl-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-071512
- JSON: https://secwatch.observer/filing/0001193125-26-071512.json
- Plain text: https://secwatch.observer/filing/0001193125-26-071512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.